Jörg J. Möhrle

Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study

Alejandro Llanos‐Cuentas, Marcus Lacerda, Ronnatrai Rueangweerayut et al. · The Lancet · 2013 · 242 citations

Antiparasitic Agent, Medicine, Malaria +6

Antimalarial activity of artefenomel (OZ439), a novel synthetic antimalarial endoperoxide, in patients with Plasmodium falciparum and Plasmodium vivax malaria: an open-label phase 2 trial

Aung Pyae Phyo, Podjanee Jittamala, François Nosten et al. · The Lancet Infectious Diseases · 2015 · 187 citations · Full text

A Pilot Randomised Trial of Induced Blood-Stage Plasmodium falciparum Infections in Healthy Volunteers for Testing Efficacy of New Antimalarial Drugs

James McCarthy, Silvana Sekuloski, Paul Griffin et al. · PLoS ONE · 2011 · 172 citations · Full text

Antimalarial activity of single-dose DSM265, a novel plasmodium dihydroorotate dehydrogenase inhibitor, in patients with uncomplicated Plasmodium falciparum or Plasmodium vivax malaria infection: a proof-of-concept, open-label, phase 2a study

Alejandro Llanos‐Cuentas, Martín Casapía, Raúl Chuquiyauri et al. · The Lancet Infectious Diseases · 2018 · 139 citations · Full text

A controlled human malaria infection model enabling evaluation of transmission-blocking interventions

Katharine A. Collins, Claire Wang, Matthew Adams et al. · Journal of Clinical Investigation · 2018 · 129 citations · Full text